<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510624</url>
  </required_header>
  <id_info>
    <org_study_id>s61580</org_study_id>
    <nct_id>NCT03510624</nct_id>
  </id_info>
  <brief_title>Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus</brief_title>
  <acronym>AREBAG</acronym>
  <official_title>Investigation of the Acute Effect of Rebaudioside A on the Glucose Excursion During an Oral Glucose Tolerance Test in 30 Patients With Type 2 Diabetes Mellitus (AREBAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the acute effect of the steviol glycoside, rebaudioside A, on the glucose
      excursion during an oral glucose tolerance test in 30 patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible individuals with type 2 diabetes mellitus will be invited for four study visits.
      During the first and third study visit, rebaudioside A or the placebo will be administered.
      During the second and fourth study visit, an oral glucose tolerance test (OGTT) will be
      executed to measure the response of administration of rebaudioside A versus placebo on the
      glucose homeostasis. The area under the curve blood glucose values during the first two hours
      of the OGTT will be compared for both conditions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) blood glucose concentrations during an OGTT</measure>
    <time_frame>0 to 2 hours after glucose challenge</time_frame>
    <description>Area under the curve blood glucose concentrations during an OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC glucose/insulin/glucagon</measure>
    <time_frame>-30 to 0 min of OGTT</time_frame>
    <description>AUC glucose/insulin/glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC glucose/insulin/glucagon</measure>
    <time_frame>0 to 30 min of OGTT</time_frame>
    <description>AUC glucose/insulin/glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC glucose/insulin/glucagon</measure>
    <time_frame>0 to 4 hours of OGTT</time_frame>
    <description>AUC glucose/insulin/glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal blood glucose</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal blood glucose excursion</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal blood glucose excursion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal serum insulin</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal serum insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal serum glucagon</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Maximal serum glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration(t) (C(t))rebaudioside A, steviol and steviol glucuronide</measure>
    <time_frame>-30 min to 4 hours of OGTT</time_frame>
    <description>Concentration of rebaudioside A, steviol and steviol glucuronide on different time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>First rebaudioside A and then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>First placebo and then rebaudioside A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebaudioside A</intervention_name>
    <description>Rebaudioside A 3g</description>
    <arm_group_label>First placebo and then rebaudioside A</arm_group_label>
    <arm_group_label>First rebaudioside A and then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Empty capsules</description>
    <arm_group_label>First placebo and then rebaudioside A</arm_group_label>
    <arm_group_label>First rebaudioside A and then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent

          -  Understand procedures

          -  Type 2 diabetes mellitus

          -  Body Mass Index (BMI): 25 - 40 kg/m2

          -  HbA1c: 6.5-8%

          -  Judged to be in good health

        Exclusion Criteria:

          -  Subject is unable to

               -  Refrain from stevia leaves, stevia extracts or steviol glycoside-containing
                  products from 5 days prior to administration of rebaudioside A or placebo until
                  discharge from the unit after the OGTT on the consecutive day.

               -  Refrain from quinine-containing products from 72h prior to administration of
                  rebaudioside A or placebo until discharge from the unit after the OGTT on the
                  consecutive day.

               -  Maintain their habitual diets and physical activity patterns and refrain from
                  engaging in strenuous physical activities from 72h prior to administration of
                  rebaudioside A or placebo until discharge from the unit after the OGTT on the
                  consecutive day.

               -  Refrain from grapefruit products from 14 days before study visit 1 until
                  discharge from the unit after the OGTT on study visit 4.

               -  Refrain from alcohol from 24h prior to administration of rebaudioside A or
                  placebo until discharge from the unit after the OGTT on the consecutive day.

               -  Refrain from caffeine containing products from 12h prior to administration of
                  rebaudioside A or placebo until discharge from the unit after the OGTT on the
                  consecutive day.

               -  Fast at least 5 hours prior to the administration of rebaudioside A or placebo on
                  study days 1 and 3.

               -  Fast at least 10 hours prior to the study days 2 and 4.

          -  Women of childbearing potential (last menstruation less than 1 year prior to
             screening) who are pregnant, lactating or planning to become pregnant during the
             study.

          -  Individuals with other forms of diabetes

          -  Current or previous treatment with any diabetes drug within 3 months prior to
             screening, except for metformin.

          -  Symptomatic hyperglycemia requiring immediate therapy during screening, in the
             judgement of the principal investigator.

          -  Evidence of significant diabetic complications.

          -  History of pancreas or beta-cell transplantation.

          -  Presence or history of clinically relevant medical, surgical or psychiatric conditions
             likely to affect the subject's safety in this trial or that could confound the study
             assessments or endpoints.

          -  Clinically relevant abnormal physical findings.

          -  Clinically significant abnormalities of vital signs:

               -  Seated systolic blood pressure outside 90-160 mmHg

               -  Diastolic blood pressure outside 40-100 mmHg

               -  Heart rate &lt;50 bpm

               -  Corrected QT (QTC) using Fridericia's formulae &gt;450 msec (for men) or &gt;470 msec
                  (for women) measured with a 12-lead electrocardiogram.

               -  Clinically significant abnormal laboratory values.

               -  Moderate or severe renal dysfunction defined as a calculated glomerular
                  filtration rate (GFR) &lt;30 ml/min.

          -  Currently active or history of alcohol abuse.

          -  Currently active or history of drug addiction or currently a regular user of drugs
             including &quot;recreational use&quot; of any illicit drug.

          -  Smoking cigarettes or using nicotine-containing products, during the last 6 months
             prior to screening, as nicotine inhibits the Transient Receptor Potential 5 (TRPM5)
             channel.

          -  Individuals for whom a major surgery is planned to occur between screening and the end
             of the trial.

          -  Previous or current use of concomitant medication, which would confound the study
             conduct or implicate a risk for safety of the participant, as judged by the
             investigator(s).

          -  History of relevant drug or food allergies or a history of severe anaphylactic
             reaction.

          -  History of hypersensitivity to the study drug or any of the excipients or to medicinal
             products with similar chemical structures.

          -  Individuals with hepatitis B and/or hepatitis C virus.

          -  Individuals with Human Immunodeficiency Virus (HIV).

          -  Participation in another clinical trial involving an investigational product within
             the 3 months preceding screening or 5-halflives of the drug studied, whichever is
             longer, prior to study supplement administration. Or, participation in any other type
             of medical research within 3 months preceding screening judged not to be
             scientifically or medically compatible with this study.

          -  Individuals who have donated or lost more than 500 ml blood or plasma within 3 months
             prior to screening.

          -  Individuals unable to swallow orally administered medication.

          -  Individuals in which catheter placement is impossible (amputation, no visible veins,
             â€¦)

          -  Individuals that cannot speak or understand the Dutch language.

          -  In the opinion of the principal investigator any other factor that could interfere
             with the subject's ability to provide informed consent or to complete the study with
             strict compliance to the study protocol, or that could hold safety concerns for the
             subject or could impact the outcome of the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Van der Schueren</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Simoens, MD</last_name>
    <phone>+3216345268</phone>
    <email>caroline.simoens@kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bart Van der Schueren, PhD</last_name>
    <phone>+32340822</phone>
    <email>bart.vanderschueren@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centrum Clinical Pharmacology</name>
      <address>
        <city>Leuven</city>
        <state>Flanders</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Simoens</last_name>
      <phone>+3216345268</phone>
      <email>caroline.simoens@kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

